advertisement
Abstract #8504 Published in IGR 5-1
Evaluation of the intraocular pressure-reducing effect of latanoprost as monotherapy in open-angle glaucoma
Mandic Z; Bojic L; Novak-Laus K; Saric DCollegium Antropologicum 2002; 26: 595-600
The objective of this study was to evaluate the intraocular pressure (IOP)-reducing effect of latanoprost as monotherapy after replacing current dual therapy in glaucoma patients. The six-month study comprised 189 patients with primary open-angle glaucoma who were treated for at least six months with two different kind of topical medications (beta-blockers, pilocarpine, dorzolamide and brimonidine). Due to local side-effects, multiple dosing regime and inadequately controlled IOP, they where switched to latanoprost 0.005% monotherapy. After switched to latanoprost, mean IOP was measured at baseline, after 15 days, and two and six months of treatment. After six-months, 178 patients had completed the study. These analyses enrolled all patients (n = 189), thus, the intention-to-treat (ITT) results were shown instead of the results of the reduced population. IOP was clinically importantly reduced from baseline level. Five patients had uncontrolled IOP. The difference between IOP before (21.9 ± 2.4) and after 15 days (17.4 ± 1.7), two months (16.7 ± 1.8) and six months (16.6 ± 1.4) was statistically significant (p < 0.001). Ninety percent patients have reached target IOP ≤ 18 mm. Conjunctional hyperemia in 18 (9%) and stinging and itching in seven (4%) patients was reported. Increased iris pigmentation was seen in three (2%) patients. The results of this study indicate that dual therapy in open-angle glaucoma can effectively be replaced by latanoprost monotherapy in many patients.
Dr. Z. Mandic, Department of Ophthalmology, University Hospital Sestre Milosrdnice, Zagreb, Croatia
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
